Proroxan hydrochloride | CAS#33025-33-1 | Anti-Adrenergic (alpha-Receptor) agent

MedKoo Cat#: 593122 | Name: Proroxan hydrochloride

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Proroxan hydrochloride is a Anti-Adrenergic (alpha-Receptor) agent.

Chemical Structure

Proroxan hydrochloride

CAS#33025-33-1

Theoretical Analysis

MedKoo Cat#: 593122

Name: Proroxan hydrochloride

CAS#: 33025-33-1

Chemical Formula: C21H24ClNO3

Exact Mass: 373.1445

Molecular Weight: 373.88

Elemental Analysis: C, 67.46; H, 6.47; Cl, 9.48; N, 3.75; O, 12.84

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Proroxan hydrochloride; AY-24,269; AY 24,269; AY24,269

IUPAC/Chemical Name

1,4-Benzodioxan, 6-(3-(3-phenylpyrrolidinyl)propionyl)-, hydrochloride

InChi Key

QQZPGRDQMBPRFY-UHFFFAOYSA-N

InChi Code

InChI=1S/C21H23NO3.ClH/c23-19(17-6-7-20-21(14-17)25-13-12-24-20)9-11-22-10-8-18(15-22)16-4-2-1-3-5-16;/h1-7,14,18H,8-13,15H2;1H

SMILES Code

O=C(C1=CC=C(OCCO2)C2=C1)CCN3CC(C4=CC=CC=C4)CC3.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 373.88 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Kundashev UK, Salenko YA, Morozov IS, Zurdinov AZ, Barchukov VG. [EFFECT OF MEDIATOR-TYPE DRUGS ON HUMAN PSYCHOPHYSIOLOGICAL STATUS DURING MODEL OPERATOR ACTIVITY]. Eksp Klin Farmakol. 2016;79(2):9-13. Russian. PubMed PMID: 27416676. 2: Ivanov IV, Bondarenko RA. [INDIVIDUAL APPROACH TO THE USE OF MEDICATIONS TO NORMALIZE SITUATIONAL ANXIETY UNDER THE PSYCHO-EMOTIONAL STRESS]. Aviakosm Ekolog Med. 2015;49(2):32-5. Russian. PubMed PMID: 26087584. 3: Ianchuk PI, Prykhod'ko TP, Pasichnichenko OM, Tieriekhov AA, Tsybenko VO. [Mechanisms of contractile action of acetylcholine on hepatic veins]. Fiziol Zh. 2011;57(1):21-8. Ukrainian. PubMed PMID: 21516830. 4: Grashin RA, Antonov VG, Karpishchenko AI, Khaĭrutdinov VR. [The free radical oxidation and antioxidant defense systems as indicators of the activity of keratinocytic proliferation in psoriasis]. Klin Lab Diagn. 2010 Jan;(1):18-24. Russian. PubMed PMID: 20205333. 5: Shabanov PD, Anokhin AG. [Evaluation of anti-seasick properties of pyrroxan and dimenhydrinate under conditions of maximal and submaximal statokinetic load in humans]. Eksp Klin Farmakol. 2005 May-Jun;68(3):50-5. Russian. PubMed PMID: 16047682. 6: Vasin MV, Ushakov IB, Koroleva LV, Lairov IA, Radchenko SN. In vitro response of mitochondrial succinate oxidase system to epinephrine in human blood lymphocytes from health individuals and patients with neurocirculatory dystonia. Bull Exp Biol Med. 2002 Oct;134(4):393-6. PubMed PMID: 12533769. 7: Morozov IS, Vetliaeva OA, Barchukov VG, Salenko IuA. [Operator activity and changes in the functional state of central adrenergic systems (a neurophysiological study)]. Eksp Klin Farmakol. 2001 Jul-Aug;64(4):13-6. Russian. PubMed PMID: 11589100. 8: Lomov IuM, Kharlanova NG, Bardakhch'ian EA. [The effect of adrenoblockers on the ultrastructural changes in the epithelium and neural elements of the small intestine of suckling rabbits with experimental cholera]. Arkh Patol. 1996 Nov-Dec;58(6):51-5. Russian. PubMed PMID: 9139594. 9: Sledkov AI, Bernarskii KV, Shilina MN. [Involvement of adrenergic mechanisms in developing the nervous syndrome of high pressure and nitrogen narcosis]. Aviakosm Ekolog Med. 1996;30(5):28-33. Russian. PubMed PMID: 8974595. 10: Bulekbaeva DE, Khanturin MR, Lakpaeva ShG. [The mechanisms of adrenergic and cholinergic effects on the lymphatic vessels of reptiles]. Fiziol Zh Im I M Sechenova. 1993 Oct;79(10):55-9. Russian. PubMed PMID: 7909473. 11: Bulekbaeva LE, Nurgalieva KB, Demchenko GA. [The characteristics of the adrenergic mechanisms regulating the lymph flow in arterial hypertension in dogs]. Fiziol Zh SSSR Im I M Sechenova. 1991 Sep;77(9):245-9. Russian. PubMed PMID: 1687134. 12: Aliev KO. [A voltametric study of the role of the noradrenaline innervation of the hippocampus in cats in paradoxical sleep]. Zh Vyssh Nerv Deiat Im I P Pavlova. 1990 Jul-Aug;40(4):714-20. Russian. PubMed PMID: 1979197. 13: Nazarov IP, Ianitskiĭ AV, Peterson RR, Popov AA. [Adrenoganglioplegia as a method of correction of hemodynamic disorders in surgical patients with initial hypotension]. Vestn Khir Im I I Grek. 1990 Apr;144(4):93-7. Russian. PubMed PMID: 1978430. 14: Kaĭfadzhian MA, Dzhanpoladian EG. [The Ca2+ reactivity and the subunit composition of myocardial actomyosin during the pyromecaine and pyrroxan treatment of experimental ischemia]. Farmakol Toksikol. 1990 Jan-Feb;53(1):27-30. Russian. PubMed PMID: 1970309. 15: Lobzin IuV, Gnoevoĭ VB, Mosichev IuN, Galemshin AA. [Clinico-psychophysiologic evaluation of the effect of pirroksan on the recovery of work capacity in sailors having had viral hepatitis A]. Voen Med Zh. 1989 Nov;(11):55-6. Russian. PubMed PMID: 2617918. 16: Shepotinovskiĭ VI, Rogozniaia NA, Mikashinovich ZI. [Digestive enzyme activity during immobilization stress and its pharmacologic correction with adrenoblockaders]. Patol Fiziol Eksp Ter. 1989 Nov-Dec;(6):49-52. Russian. PubMed PMID: 2576468. 17: Shepotinovskiĭ VI, Mikashinovich ZI, Shapiro GA, Ivanova OV. [Functional biochemical changes and their pharmacologic correction by pirroksan in renal ischemia]. Patol Fiziol Eksp Ter. 1989 Jul-Aug;(4):24-7. Russian. PubMed PMID: 2574439. 18: Lelevich VV, Pron'ko PS, Liopo AV, Deniskovets AA. [Effect of drugs possessing antialcoholic activity on ethanol pharmacokinetics]. Farmakol Toksikol. 1989 Jul-Aug;52(4):85-8. Russian. PubMed PMID: 2572455. 19: Dzhanpoladian EG, Karagezian KG, Sambelian VM, Aloian GA. [Effect of anti-angina therapy on phospholipid levels of the myocardium in ischemic lesions]. Kardiologiia. 1988 Oct;28(10):88-90. Russian. PubMed PMID: 3147341. 20: Korovin KF, Kovalev OA, Iampol'skaia LI, Samokhin GS. [Aldosterone content of the blood and tissues in rats with an altered level of adrenergic activity]. Probl Endokrinol (Mosk). 1988 Mar-Apr;34(2):62-4. Russian. PubMed PMID: 2839821.